Recro Pharma, Inc.

Good day, ladies and gentlemen, and welcome to the RECRO third quarter 2021 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this conference call may be recorded. I would now like to hand the conference over to Stephanie Diaz of RECRO's Investor Relations Group. Please go ahead.

Thank you. Hello, and thank you for joining us. On today's call, we have David Enloe, President and CEO, and Ryan Lake, Chief Financial Officer. Today we will be providing an overview of RECRO's contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended September 30th, 2021. After our prepared remarks, we will welcome your questions. Before we begin, I'd like to caution that comments made during this conference call today, November 9th, 2021, will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the current beliefs of the company, which involve a number of assumptions, risks, and uncertainties. Actual results could differ from these statements, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. Our earnings press release in this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at RecroCDMO.com. With that, I will turn the call over to David Enloe, Recro's President and CEO.

Thank you, Stephanie, and thank you to everyone who has dialed in and to those who are participating today via webcast. During the third quarter, RECRO significantly increased and accelerated its growth trajectory through the acquisition of IRISIS, a CDMO with capabilities that greatly complement our own. We believe that through the joining of these two companies, we have created an organization best positioned to achieve sustainable growth and profitability. The impact of the company's broadened geographic footprint and expanded service offerings facilitated a number of new business wins during the period, spanning the full range of RECRO's capabilities at both locations, including new client contracts for oral solid dose projects to be carried out in Georgia, new client contracts for advanced dosage formats to be performed in San Diego, expanded contracts with existing clients in both Georgia and San Diego, contracts for commercial production, as well as contracts for clinical trial materials, a contract that will utilize the high-potency suite recently put into operation in Georgia, and contracts for clinical trial services such as packaging and labeling. I will provide details on each of these achievements following an overview of our Q3 and nine-month financial results. For that, I will turn the call over to Ryan.